Summary
5GH Chart
Is Guardant Health (GH) Stock Outpacing Its Medical Peers This Year?
Here is how Guardant Health (GH) and Collegium Pharmaceutical (COLL) have performed compared to their sector so far this year.
Guardant Health Beats Expectations: Shield, Quest, And AI Catalysts
Guardant Health, Inc.'s Shield ADLT reimbursement, Quest, and guidance raise show good adoption momentum. These positives keep me bullish on GH stock. Their oncology business remains the revenue anchor. Biopharma & Data also came in with good margins and provided some diversification. GH's recent Q3 report showed growing revenues, more Shield tests, and, ex-Screening, they became cash flow positive earlier than expected.
Guardant Health: Business Continues To Gather Pace
Guardant Health delivered extremely robust Q3 results and raised full-year guidance, with Reveal and Shield beginning to make material contributions. Guardant's therapy selection and biopharma businesses also remain strong. While GH is burning cash, this is in support of the screening business' rapid expansion. The company is now on a clear path to breakeven in the next few years.
Guardant Health Inc. (5GH) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Guardant Health Inc. ever had a stock split?
Guardant Health Inc. Profile
| Professional Services Industry | Industrials Sector | Helmy Eltoukhy CEO | XFRA Exchange | US40131M1099 ISIN |
| US Country | 1,999 Employees | - Last Dividend | - Last Split | 4 Oct 2018 IPO Date |
Overview
Guardant Health, Inc. is a pioneer in the precision oncology field, dedicated to enhancing cancer management through a comprehensive portfolio of blood and tissue tests, expansive data sets, and sophisticated analytics. Operating both within the United States and internationally, this company leverages cutting-edge technology to transform cancer care, making it more personalized and effective. Since its establishment in 2011, Guardant Health has been at the forefront of innovation in oncology, partnering with key industry players like Illumina, Inc., to push the boundaries of cancer research and treatment further.
Products and Services
- Guardant360: A liquid biopsy test that offers comprehensive genomic profiling of cancer from a simple blood draw, enabling non-invasive tumor genetic analysis.
- Guardant360 LDT: An extension of the Guardant360 service, tailored for more specific diagnostic needs through a laboratory-developed test approach.
- Guardant360 CDx Test: Designed as a companion diagnostic tool, this test helps in identifying patients who could benefit from specific cancer therapies based on their genetic markers.
- Guardant360 Response Test: This test monitors treatment response and disease progression, aiding in the timely adjustment of therapeutic strategies.
- Guardant360 TissueNext Test: Offers a more comprehensive genetic profile by combining blood-based and tissue-based genomic testing, ensuring no valuable data is missed.
- GuardantINFINITY Test: Aimed at providing a deeper understanding of tumor genetics over time, this test is crucial for uncovering resistance mechanisms and guiding long-term treatment plans.
- GuardantConnect: An integrated software solution that connects patients with actionable genetic alterations to clinical studies, improving accessibility to innovative treatments.
- GuardantOMNI Test: Focused on patients with advanced-stage cancer, this test screens for a broad array of genetic markers to inform treatment decisions.
- GuardantINFORM: A research platform that utilizes in-silico modeling to explore tumor evolution and resistance mechanisms across various cancers, aiding in the development of next-generation therapies.
- Shield Test: A novel approach for early cancer detection through the analysis of blood samples, aiming to improve survival rates through early intervention.
- Guardant Reveal Test: Specifically designed for early-stage cancer patients, this test guides adjuvant treatment selection to minimize recurrence risk.
- Smart Liquid Biopsy Platform: This innovative platform supports the development of precision oncology by offering flexible, scalable, and accurate liquid biopsy testing.
- Guardant Galaxy: An AI-backed digital pathology platform that enhances the detection of cancer biomarkers, leveraging artificial intelligence to improve diagnostic accuracy.
